Publication | Closed Access

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

Hematological MalignancyLymphoid NeoplasiaAutoimmune DiseaseMedicineR-chop RegimensImmunologyHematologyPathologyImmune SurveillanceAutoimmunityAdult T-cell Leukemia-lymphomaImmunotherapyOncology